Eli Lilly & Co. (LLY)

113.19
NYSE : Health Technology
Prev Close 111.39
Day Low/High 111.33 / 113.82
52 Wk Low/High 101.36 / 132.13
Avg Volume 3.19M
Exchange NYSE
Shares Outstanding 960.13M
Market Cap 106.95B
EPS 3.10
P/E Ratio 24.75
Div & Yield 2.58 (2.21%)

Latest News

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data From Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial In Psoriatic Arthritis

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data From Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial In Psoriatic Arthritis

Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis

ACR 2019: Lilly Presents Positive New Data From COAST-X, A Phase 3 Study Of Taltz® (ixekizumab) In Patients With Non-Radiographic Axial Spondyloarthritis

ACR 2019: Lilly Presents Positive New Data From COAST-X, A Phase 3 Study Of Taltz® (ixekizumab) In Patients With Non-Radiographic Axial Spondyloarthritis

Based on these positive results, Lilly has submitted for U.S. regulatory approval for adults with active non-radiographic axial spondyloarthritis

Eli Lilly Has the Base to Support a New Rally

Eli Lilly Has the Base to Support a New Rally

Shares of the pharmaceutical company received a quant upgrade Monday.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CECO, DOC, FC, GLW, GNE, GORO, IVR, LLY, MR, NTB, NTR, PCYO, SENEB Downgrades: CLGX, HIMX, IRT, NCR, NGS, NMFC, PRTY, RLGY, TUSK Initiations: ARLO, GH, PRNB Read on to get TheStreet Quant Ratings' detailed report:

Lilly Reinforces Its Commitment To Rheumatology Through Data Showcased At The ACR/ARP Annual Meeting

Lilly Reinforces Its Commitment To Rheumatology Through Data Showcased At The ACR/ARP Annual Meeting

Thirty-one abstracts supporting Taltz® and Olumiant® highlight the latest innovative data in axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus and rheumatoid arthritis

Lilly Announces The Pricing Terms Of Its Cash Tender Offer For Up To $2,000,006,000 Aggregate Principal Amount Of Its Outstanding Debt Securities

Lilly Announces The Pricing Terms Of Its Cash Tender Offer For Up To $2,000,006,000 Aggregate Principal Amount Of Its Outstanding Debt Securities

INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal amount of its outstanding debt securities.

Lilly Announces The Early Tender Results And Upsizing Of Its Pending Cash Tender Offer To Up To $2,000,006,000 Aggregate Principal Amount Of Its Outstanding Debt Securities

Lilly Announces The Early Tender Results And Upsizing Of Its Pending Cash Tender Offer To Up To $2,000,006,000 Aggregate Principal Amount Of Its Outstanding Debt Securities

INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities.

Eli Lilly And Company To Present Multiple Abstracts For LOXO-305 At ASH 2019

Eli Lilly And Company To Present Multiple Abstracts For LOXO-305 At ASH 2019

INDIANAPOLIS, Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to...

Lilly To Participate In Credit Suisse 28th Annual Healthcare Conference

Lilly To Participate In Credit Suisse 28th Annual Healthcare Conference

INDIANAPOLIS, Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28 th Annual Healthcare Conference on Wednesday, November 13, 2019.

Boehringer Ingelheim And Lilly Modernise Alliance To Focus Full Expertise On Jardiance®

Boehringer Ingelheim And Lilly Modernise Alliance To Focus Full Expertise On Jardiance®

- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease - Alliance to continue to include three product families - empagliflozin, linagliptin and insulin...

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

LLY: Insiders Vs. Shorts

LLY: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Lilly (Eli) & Co is the #102 most shorted of the S&P 500 components, based on 5.89 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

McDonald's, Microsoft, Amazon and More - Biggest Earnings This Week

McDonald's, Microsoft, Amazon and More - Biggest Earnings This Week

Here's list of key companies to watch the week of October 21st.

Lilly Announces Cash Tender Offer For Up To $2.0 Billion Aggregate Principal Amount Of Its Outstanding Debt Securities

Lilly Announces Cash Tender Offer For Up To $2.0 Billion Aggregate Principal Amount Of Its Outstanding Debt Securities

INDIANAPOLIS, Oct. 24, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $2.

Texas Instruments, Boeing, Nike, Snap and Microsoft - 5 Things You Must Know

Texas Instruments, Boeing, Nike, Snap and Microsoft - 5 Things You Must Know

U.S. stock futures are mixed Wednesday and the global chip sector slumps following a revenue warning from Texas Instruments; Boeing, Caterpillar, Microsoft and Tesla to report earnings; Boeing's head of commercial airlines will leave the aerospace giant amid the 737 MAX crisis; Nike CEO Mark Parker to step down.

Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

- Revenue in the third quarter of 2019 grew 3 percent, driven by 8 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, and Cyramza, contributed 12 percentage points of revenue growth and represented approximately 44 percent of total revenue.

Enrique Conterno, Senior Vice President And President Of Lilly Diabetes And Lilly USA, To Retire At End Of Year; Mike Mason To Succeed Conterno

Enrique Conterno, Senior Vice President And President Of Lilly Diabetes And Lilly USA, To Retire At End Of Year; Mike Mason To Succeed Conterno

INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of...

Eli Lilly Expected to Earn $1.40 a Share

Eli Lilly Expected to Earn $1.40 a Share

Eli Lilly revenue expected to fall 9.3% to $5.5 billion.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

Lilly Declares Fourth-Quarter 2019 Dividend

Lilly Declares Fourth-Quarter 2019 Dividend

INDIANAPOLIS, Oct. 21, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2019 of $0.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Eli Lilly Phase 3 Pancreatic Cancer Study Fails to Meet Primary Endpoint

Eli Lilly Phase 3 Pancreatic Cancer Study Fails to Meet Primary Endpoint

The late-stage trial of patients with metastatic pancreatic cancer 'did not meet its primary endpoint of overall survival,' Eli Lilly says.

Lilly Announces Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint Of Overall Survival

Lilly Announces Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint Of Overall Survival

INDIANAPOLIS, Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with...

Lilly Presents Positive Results For Taltz® (ixekizumab) In Pediatric Patients With Moderate To Severe Plaque Psoriasis At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Lilly Presents Positive Results For Taltz® (ixekizumab) In Pediatric Patients With Moderate To Severe Plaque Psoriasis At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Taltz is the first and only IL-17A inhibitor with published clinical trial results in pediatric patients with moderate to severe plaque psoriasis

Lilly's REYVOW™ (lasmiditan), The First And Only Medicine In A New Class Of Acute Treatment For Migraine, Receives FDA Approval

Lilly's REYVOW™ (lasmiditan), The First And Only Medicine In A New Class Of Acute Treatment For Migraine, Receives FDA Approval

- The approval of REYVOW is significant because it represents the first new class of acute migraine treatment approved by the FDA in more than two decades

Lilly To Unveil New Data For The Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Lilly To Unveil New Data For The Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Research from Taltz®, Olumiant® and mirikizumab highlight the impact Lilly's medicines may have for patients around the world

Lilly's CYRAMZA® (ramucirumab) Phase 3 Data In First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published In The Lancet Oncology

Lilly's CYRAMZA® (ramucirumab) Phase 3 Data In First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published In The Lancet Oncology

CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations

TheStreet Quant Rating: B- (Buy)